

## EQA round: HIL1/26 - Serum Indices

Deadline: 17.4.2026

Setup: groups - P (manufacturer of instrument); Slovakia; minimal size of the groups n = 5

RoM = robust average	AV = assigned value	D <sub>max</sub> = acceptable difference
SD = standard deviation	U <sub>AV</sub> = expanded uncertainty of the assigned value (k = 2)	LL = lower limit
CV = coefficient of variation		UL = upper limit
N <sub>tot</sub> = total number of the results		N <sub>eva</sub> = number of the results assessed
N <sub>out</sub> = number of the results removed before calculation		N <sub>suc</sub> = number of successful results
		S <sub>rel</sub> = relative success

Test Sample Group	[unit]	RoM	SD	CV [%]	N <sub>tot</sub>	N <sub>out</sub>	Comparability					N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub> [%]	
							AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL				
<b>(507) Bilirubin total</b>	[μmol/L]				13							13	13	100	
<b>Sample A</b>		157	14	8,9	13		CVP	157	2,5	20%	125	189	13	13	100
Other					13	0	4x 1, 3x 58, 4x 60, 2x 162					13			
<b>Sample B</b>		461	22	4,8	13		CVP	449	5,8	20%	359	539	13	13	100
Other					13	0	4x 1, 3x 58, 4x 60, 2x 162					13			
<b>(501) Hemolytic index (quantitative)</b>	[μmol/L]				6							6	6	100	
<b>Sample A</b>		147	4,6	3,1	6		CVP	141	1,4	20%	112	170	6	6	100
Other					6	0	2x 1, 4x 60					6			
<b>Sample B</b>		32,9	6,4	19	6		CVP	32,6	0,92	28%	23,4	41,8	6	6	100
Other					6	0	2x 1, 4x 60					6			
<b>(502) Icteric index (quantitative)</b>	[μmol/L]				6							6	6	100	
<b>Sample A</b>		147	35	24	6		CVP	156	4,8	30%	109	203	6	6	100
Other					6	0	2x 1, 4x 60					6			
<b>Sample B</b>		509	31	6,2	6		CVP	493	6,8	20%	394	592	6	6	100
Other					6	0	2x 1, 4x 60					6			
<b>(503) Lipemic index (quantitative)</b>	[g/L]				6							6	6	100	
<b>Sample A</b>		1,44	0,015	1	6		CVP	1,47	0,015	20%	1,17	1,77	6	6	100
Other					6	0	2x 1, 4x 60					6			
<b>Sample B</b>		4,29	0,074	1,7	6		CVP	4,47	0,089	20%	3,57	5,37	6	6	100
Other					6	0	2x 1, 4x 60					6			